Effect of gastric acid suppressants and prokinetics on peritoneal dialysis-related peritonitis

Table 6 Acid-suppressive therapy and other medications in enteric peritonitis group and non-enteric peritonitis group n (%)

		Included peritonitis episode (n = 81)
		Enteric peritonitis (n = 26)	Non-enteric peritonitis (n = 55)	P value
Sterile peritonitis included in NEP group	Use of PPIs	3 (11.5)	8 (14.5)	1.000
	Use of H2Bs	6 (23.1)	15 (27.3)	0.687
	Use of other antacids	1 (3.8)	5 (9.1)	0.658
	Use of prokinetics	5 (19.2)	18 (32.7)	0.209
	Use of immunosuppressants	2 (7.7)	7 (12.7)	0.501
Sterile peritonitis excluded in NEP group	Use of PPIs	3 (11.5)	5 (14.3)	1.000
	Use of H2Bs	6 (23.1)	9 (25.7)	0.818
	Use of other antacids	1 (3.8)	3 (8.6)	0.629
	Use of prokinetics	5 (19.2)	13 (37.1)	0.129
	Use of immunosuppressants	2 (7.7)	5 (14.3)	0.688

PPIs: Proton pump inhibitors; H2Bs: H2-blockers. NEP: Non-enteric peritonitis.